EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted DNA Sequencing for Tailored Therapies in Children with Extracranial Solid Tumors

Nataliya A Andreeva, Tatyana V Shamanskaya, Denis Y Kachanov iD, Nikolay V Zhukov iD, Nina V Gegeliya, Ruslan H Abasov, Natalia Y Usman iD, Anastasia V Protsvetkina, Dmitry M Konovalov iD, Dmitry V Litvinov, Natalia V Myakova, Nikolay S Grachev und 2 weitere

International Journal of Molecular Sciences · 26.11.2025 · 26 (23) · 11463

DOI: 10.3390/ijms262311463 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.11.2025. Verfasst von Nataliya A Andreeva und 13 weiteren Autor:innen. Beteiligte Einrichtung: Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow 117198, Russia. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Neoplasms, Molecular Targeted Therapy, Precision Medicine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Next-generation sequencing (NGS) is instrumental for clinical decisions on molecularly targeted therapy (TT). In pediatric oncology, TT is a relatively rare choice administered chiefly on a tumor-agnostic basis. The investigation enrolled 304 pediatric patients with extracranial solid tumors that were diagnosed and treated in 2018–2023. Tumor DNA was sequenced using a customized QiaSeq panel (Qiagen, Hilden, Germany) of genes known to be relevant for pediatric solid tumors, including ALK, BRAF, BRCA1/2, EGFR, FGFR1, KIT, MAP2K1/2, NF1, PDGFRA/B, PIK3CA, PTEN, PTPN11, RAS family genes, etc. The assay allowed detection of nucleotide substitutions and small insertions/deletions, as well as gene copy number alterations. TT sensitivity predictors were identified in 120/304 cases (39.5%): Tier II in 83 patients, Tier IB in 32 patients (almost always ALK in neuroblastoma, n = 31) and Tier IA in 5 patients: BRAF p.V600E (n = 3) and NF1 aberrations (n = 2). TT commenced in 21/304 cases (6.9%), often first-line or as a first relapse therapy (14/21 cases), combined with chemotherapy (TT-CT) in 13 cases. The median of TT duration was 10.9 (range 0.8–43.5) months for single-mode and 12.3 (0.3–61.5) months for TT-CT. Clinical benefit rate was achieved in 14/21 patients (66.7%). At the time of writing, nine patients (42.8%) have no progression and are still on treatment for 30.4 months (range 10.3–40.5) after the start of TT. The median time to the best response to TT was 6 (range 0.8–12.3) months. The tolerance was generally good: the therapy was discontinued for toxicity in only one case. The study provides a TT-focused prospective analysis still rare in pediatric oncology. The outcomes indicate satisfactory tolerance and promising efficacy of TT, prompting an update of current treatment standards for several pediatric cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

High-Throughput Nucleotide SequencingNeoplasmsMolecular Targeted TherapyPrecision MedicineHumansChildFemaleMaleChild, PreschoolAdolescentInfantMutationBiomarkers, TumorDNA Copy Number Variations

Stichwörter der Autor:innen

DNA sequencingNGSchildrenmolecular therapyneuroblastomaprecision treatmenttargeted treatment

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow 117198, Russia.
  • Research Institute of Medical Cell Technologies, Yekaterinburg 620026, Russia.

ORCID-Profile: Denis Y Kachanov, Nikolay V Zhukov, Natalia Y Usman, Dmitry M Konovalov

Zitieren

APA

Andreeva, N. A., Shamanskaya, T. V., Kachanov, D. Y., Zhukov, N. V., Gegeliya, N. V., Abasov, R. H., Usman, N. Y., Protsvetkina, A. V., Konovalov, D. M., Litvinov, D. V., Myakova, N. V., Grachev, N. S., Novichkova, G. A., & Druy, A. E. (2025). Targeted DNA Sequencing for Tailored Therapies in Children with Extracranial Solid Tumors. International Journal of Molecular Sciences, 26(23), 11463. https://doi.org/10.3390/ijms262311463

Vancouver

Andreeva NA, Shamanskaya TV, Kachanov DY, Zhukov NV, Gegeliya NV, Abasov RH, et al. Targeted DNA Sequencing for Tailored Therapies in Children with Extracranial Solid Tumors. International Journal of Molecular Sciences. 2025;26(23):11463. doi:10.3390/ijms262311463

BibTeX
@article{Andreeva2025,
  author = {Andreeva, Nataliya A and Shamanskaya, Tatyana V and Kachanov, Denis Y and Zhukov, Nikolay V and Gegeliya, Nina V and Abasov, Ruslan H and Usman, Natalia Y and Protsvetkina, Anastasia V and Konovalov, Dmitry M and Litvinov, Dmitry V and Myakova, Natalia V and Grachev, Nikolay S and Novichkova, Galina A and Druy, Alexander E},
  title = {Targeted DNA Sequencing for Tailored Therapies in Children with Extracranial Solid Tumors},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {23},
  pages = {11463},
  doi = {10.3390/ijms262311463}
}
Kostenlos starten →